The House Energy & Commerce Committee on Wednesday (May 18) passed 55-0 comprehensive user fee legislation that includes new language giving FDA authority to require sponsors of pediatric cancer trials to study a combination of drugs, rather than one drug at a time, in order to speed development of drugs that treat relapsed cancer. E&C leaders signaled they may still add measures to hike FDA’s oversight of cosmetic products and laboratory-developed tests to align with provisions in the Senate health...